LifeSci Advisors Announces 12th Board Appointment Through Its Board Placement Initiative
NEW YORK, Jan. 31, 2018 (GLOBE NEWSWIRE) -- LifeSci Advisors, an investor relations and corporate communications firm focused on the life sciences sector, today announces the 12th appointment of a female executive to a life sciences company board as part of its Board Placement Initiative (BPI). LifeSci Advisors launched BPI in the summer of 2016 with the goal of connecting female executives in the life sciences industry with companies looking for board candidates.
LifeSci is pleased to share that Dr. Carol L. Brosgart has joined the Board of Directors of ABIVAX, a biotechnology company harnessing the immune system to develop a functional cure for HIV and treatments for inflammatory/autoimmune diseases and cancer. Dr. Brosgart is a Clinical Professor of Medicine, Epidemiology and Biostatistics at the Institute for Global Health, Department of Medicine, University of California in San Francisco, CA.
"I am pleased to join the board of ABIVAX and help this progressive company continue to advance their clinical pipeline forward," said Dr. Brosgart. "I look forward to contributing to the strategic and clinical development oversight of the company, and I am thankful to LifeSci for facilitating this placement."
Dr. Brosgart has served as an independent director on the Boards of both public and privately-held biotechnology companies, as a member of the Federal US CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment, and was the Senior Advisor on Science and Policy to the Division of Viral Hepatitis at the CDC. She has held numerous senior management positions within biotechnology and health care. Dr. Brosgart was the Chief Medical Officer for Alios BioPharma (now Johnson & Johnson), a biotech company developing therapies to treat viral diseases. Dr. Brosgart joined Alios from Children's Hospital & Research Center in Oakland, California, where she served as Senior Vice President and Chief Medical Officer. For eleven years Dr. Brosgart held a number of senior management positions at Gilead Sciences. While Vice President of Clinical Research at Gilead she was responsible for the clinical development and approval by the FDA and by regulatory authorities worldwide of two antiviral therapies - Viread® for the treatment of HIV, and Hepsera® for the treatment of chronic hepatitis B.
Prior to Gilead, Dr. Brosgart worked for more than 20 years in public health, clinical care, research, and teaching. She was among the first physicians in the United States to recognize and treat patients with HIV/AIDS. Dr. Brosgart was the founding Medical Director of the East Bay AIDS Center. She led NIH clinical trials as a member of the Community Programs for Clinical Research on AIDS (CPCRA), chaired the CPCRA Scientific Advisory Committee, and contributed to HIV antiretroviral drug development, and to the development of prophylactic and treatment agents for opportunistic and malignant complications of HIV. Dr. Brosgart received her B.S. in community medicine from the University of California, Berkeley (UCB), her M.D. from the University of California, San Francisco (UCSF), and her residency training in Pediatrics (UCSF) and Public Health and Preventive Medicine (UCB). She has published extensively in the areas of infectious diseases, focusing on antiviral therapy for HIV, HBV, CMV and related public health policy.
"We are confident that Carol's insights and experience will be a huge asset to ABIVAX as they continue to develop their clinical programs," said Michael Rice, President and Co-Founder, LifeSci Advisors. "We're very happy to have made the introduction and look forward to announcing more successful appointments through our Board Placement Initiative in the near future."
"We are thrilled that Carol is bringing her expertise and deep industry knowledge to our board," said Dr. Hartmut J. Ehrlich, Chief Executive Officer, ABIVAX. "Her vast wealth of experience and passion for treating patients with HIV/AIDS will be invaluable to the company's clinical strategy, and we are pleased to have found Dr. Brosgart through LifeSci's Board Placement Initiative."
LifeSci Advisors' Board Placement Initiative (BPI) was launched with the goal of helping companies in the life sciences industry diversify and strengthen their company boards. Introductions between companies and eligible board candidates are made after LifeSci has met with a company's management team or Board regarding the skills and expertise they are seeking in a candidate, and after the LifeSci team has properly vetted the board candidates. BPI now has helped to place 12 women on corporate boards and is looking to continue this success. With a proprietary network comprised of board-ready women, LifeSci Advisors hopes that BPI can become a valuable platform where both female executives and life sciences companies are able to network and to grow.
BPI is accepting resumes from interested candidates and referrals on an on-going basis. To find out how you can use the BPI network for your next board candidate search, visit www.lifesciadvisors.com/board-diversity-initiatives. Inquiries, resume submissions, and open board seat referrals can be sent to email@example.com.
LifeSci Advisors, LLC (www.lifesciadvisors.com) is the largest investor relations consultancy in the life sciences industry, founded to provide companies with a multi-faceted approach to investor communications and outreach. With a global focus and reach, the firm provides the highest quality service for its clients through its deep sector specialization. LifeSci's team of MDs and PhDs enables the firm to better understand clients' R&D, regulatory and commercial strategies, and its team of financial services, investor relations and public relations specialists helps clients effectively communicate to the marketplace. This combination of life sciences, financial services, and investor relations competencies allows LifeSci Advisors to provide an invaluable and unique service offering to clients.
LifeSci Partners (www.lifescipartners.com) is the leading provider of consulting services in the areas of investor relations, public relations, corporate communications and capital markets advisory. Combining deep domain expertise in the life sciences with decades of experience in capital markets and public relations, LifeSci Partners delivers unparalleled services to life sciences companies globally.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LifeSci Advisors, LLC via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Bio-Fence announces a breakthrough in Food Safety18.1.2019 08:11 | Pressemelding
The company have successfully completed a field trial of its new anti-microbial coating technology. The trials demonstrated a significant reduction in bacterial contamination during sensitive food production processes ASHDOD, Israel, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Bio-Fence innovating coating technology announced today the successful completion of an intensive field trial on its innovative anti-microbial technology Pentagon. The trial was held in "Milouoff" (http://www.milouoff.co.il), one of the largest Ready to Eat poultry production sites in Israel and demonstrated superior results for Bio-Fence technology compared to alternatives. According to Mrs. Shiran Davidi, QA manager at Milouoff: “Bio-Fence technology seems to have clear benefits over existing antimicrobial solution. It is safe, highly potent and rechargeable.” The trial involved monitoring the performance of an epoxy floor coated with Bio-Fence anti-microbial technology compared to either commercial Silver Ion coating an
ERYTECH Presents TRYbeCA-1 Trial-in-Progress Poster at the 2019 ASCO GI Annual Meeting18.1.2019 07:00 | Pressemelding
LYON, France and CAMBRIDGE, Mass., Jan. 18, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, announced that a poster entitled “TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)” will be presented today at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in San Francisco. The poster (Abstract # TPS471) will be available at www.erytech.com after presentation at the conference. In September 2018, the TRYbeCA-1 trial was initiated. The Trial-in-Progress poster will provide an update on the study progress with investigators sites that have been initiated in multiple countries and actively recruiting patients. The trial is planned to enroll approximately 500 patients with
Fossil Group Enters Agreement To Sell Select Smartwatch Technology To Google17.1.2019 18:30 | Pressemelding
Transaction Unlocks Growth Opportunities for Fossil Group’s Wearables Business RICHARDSON, Texas, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Today, Fossil Group (NASDAQ:FOSL) announced its plan to sell to Google for $40 million intellectual property (IP) related to a smartwatch technology currently under development by Fossil Group. As part of the transaction, a portion of Fossil Group’s research and development (R&D) team currently supporting the transferring IP will join Google. Fossil Group retains more than 200 R&D team members to focus on innovation and product development. The transaction showcases Fossil Group and Google’s shared investment in the wearables industry. In recent years, smartwatches have become Fossil Group’s fastest growing category. The company successfully developed and launched smartwatches across 14 of its owned and licensed brands. “Fossil Group has experienced significant success in its wearables business by focusing on product design and development informed by our
Calgon Carbon Corporation Announces Global Price Increase17.1.2019 17:16 | Pressemelding
Pittsburgh, PA, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Calgon Carbon Corporation today announced a global price increase, effective February 1, 2019, where contracts permit, on all activated carbon products and related equipment due to a continued escalation in raw material costs and transportation expenses. The increase is expected to range between 10-15%, depending on the specific product, raw material type, services provided, and global market dynamics. The primary raw materials used for producing activated carbon are coal, coconut shell, and wood, each of which has gone up in price. Additionally, costs associated with both operating manufacturing facilities and transporting materials have also escalated. “Calgon Carbon’s raw material costs have increased significantly. Despite every effort to offset these increases through continuous improvements, the recent rise in raw material costs has exceeded our efforts,” said Jim Coccagno, Chief Commercial Officer for Calgon Carbon Corporation. “
Taconic Biosciences’ Animals Complete Most Recent Mission to the International Space Station17.1.2019 15:29 | Pressemelding
RENSSELAER, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces the completion of a recent mission to the International Space Station. This project represents a collaboration between the International Space Station (ISS) National Lab, National Aeronautics and Space Administration (NASA), Bioserve Space Technologies with support from the Leidos Corporation, and Taconic. Taconic has participated in several spaceflight missions with NASA since 1985. Most recently, as part of the science and research investigation payloads supported by the SpaceX Commercial Resupply Services missions, Taconic prepared mice to live aboard the International Space Station for extended periods. Previous spaceflight studies demonstrated that mice undergo rapid loss of muscle and bone mass, resembling accelerated aging. Therefore, mice exposed to microgravity via spaceflight are a valuable model to understand and devel
MPP Global Bridges the Innovation Gap by Centralising Physical and Digital Subscriber Management and Billing in a Single Cloud Platform17.1.2019 12:29 | Pressemelding
WARRINGTON, UK, Jan. 17, 2019 (GLOBE NEWSWIRE) -- MPP Global, the technology company that delivers eSuite, the world’s smartest subscriber management & billing platform, announces the launch of pivotal new functionality which enables media organisations to seamlessly create and manage the sale of physical subscriptions. This positions eSuite as the complete physical and digital subscription management solution. The development of this industry-first functionality was borne out of the common challenge for publishers when managing multiple systems for deploying bundled print and digital subscriptions. This is inflexible for publishers and limits choice for their customers, restricting the ability to seamlessly create and offer digital and print subscription bundles. Despite increased consumer uptake of digital subscriptions, print still accounts for almost 90% of circulation revenues globally. To drive reader revenues successfully, publishers require functionality to execute complementar